North Dakota House Bill HB1543

North Dakota 2026 1st Special Session

Caption

AN ACT to provide for a legislative management study regarding prescription drug pricing and the maximum fair price as determined by the federal government.

Summary

House Bill No. 1543 mandates a legislative management study on prescription drug pricing during the 2025-26 interim. The study will focus on the maximum fair price for drugs as determined by the federal government, particularly in light of the Federal Inflation Reduction Act of 2022. It aims to analyze the potential cost savings for the state and consumers by examining the overlap with drugs covered by the public employees retirement system. Input will be gathered from relevant stakeholders, including the public employees retirement system, the insurance commissioner, and the state board of pharmacy.

Impact

The bill will not change existing laws directly but will initiate a study that could lead to future legislative recommendations regarding prescription drug pricing in North Dakota. Depending on the findings, it may influence state policies related to drug pricing and negotiations, potentially affecting state expenditures and consumer costs.

Sentiment

The sentiment surrounding HB1543 appears to be largely positive, as indicated by the overwhelming support in the House (89-4) and Senate (44-1) votes. Legislators seem to recognize the importance of addressing prescription drug pricing and are supportive of studying the issue to find potential savings for the state and its residents.

Contention

There are no notable points of contention reported in the discussions or voting history for HB1543. The broad support suggests that legislators are unified in their desire to investigate prescription drug pricing without significant opposition.